Good results in lab and pilot studies lead to larger human trials. Here are some of the most promising recent findings.
- Serratiopeptidase reduced vessel inflammation
Standard anti-inflammatory medications for inflammatory conditions have serious long-term adverse effects. In the lab, doctors gave the anti-inflammatory super-enzyme, serratiopeptidase (SRP), to mice with blood vessel inflammation. In aortic tissue, levels of a pro-inflammatory bacterial toxin, lipopolysaccharides (LPS), linked to heart disease, decreased significantly, along with the pro-inflammatory cytokines Interleukin-1, -2, and -6, and tumor necrosis factor-alpha.
Reference: Current Issues in Molecular Biology; 2023, Vol. 45, No. 3 101097, 1441
